MarketCap
Facebook
X
Telegram
Curis Accounts Payables | CRIS
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.61 M | 3.02 M | 3.17 M | 3.19 M | 6.42 M | 4.17 M | 4.46 M | 2.91 M | 5.42 M | 5.88 M | 4.22 M | 2.35 M | 2.04 M | 2.5 M | 2.36 M | 2.62 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.42 M | 2.04 M | 3.77 M |
Quarterly Accounts Payables Curis
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.74 M | 4.44 M | 4.1 M | 5.1 M | 3.02 M | 3.82 M | 2.45 M | 3.63 M | 3.17 M | 5.22 M | 2.69 M | 2.64 M | 3.19 M | 5.76 M | - | 4.28 M | 6.42 M | 3.51 M | 4.05 M | 3.43 M | 4.17 M | 4.17 M | 4.17 M | 4.17 M | 4.46 M | 4.46 M | 4.46 M | 4.46 M | 2.91 M | 2.91 M | 2.91 M | 2.91 M | 5.42 M | 5.42 M | 5.42 M | 5.42 M | 5.88 M | 5.88 M | 5.88 M | 5.88 M | 4.22 M | 4.22 M | 4.22 M | 4.22 M | 2.35 M | 2.35 M | 2.35 M | 2.35 M | 2.04 M | 2.04 M | 2.04 M | 2.04 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.74 M | 2.04 M | 3.78 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
13.2 M | $ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
21.2 M | $ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
1.69 M | $ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
3.98 M | $ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
108 M | $ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
4.27 M | $ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
116 M | $ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
2.72 M | $ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
4.91 M | $ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
2.37 B | $ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
45.4 M | $ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
166 M | $ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
3.59 B | $ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
3.87 M | $ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
6.04 M | $ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
62.6 M | $ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
714 K | $ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
877 K | $ 1.87 | 2.75 % | $ 590 K | USA |
 |
Aquestive Therapeutics
AQST
|
29.9 M | $ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.24 M | $ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
19.2 M | $ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
921 K | $ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Arvinas
ARVN
|
24.4 M | $ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
1.17 M | $ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
897 K | $ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
127 K | $ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
83 M | $ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
3.31 M | $ 16.3 | 1.26 % | $ 2.19 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
12.9 M | $ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
139 M | $ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
65.5 M | $ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
36.2 M | $ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
15.8 M | $ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
9.67 M | $ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
579 K | $ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
10.2 M | $ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
432 M | $ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
3.58 B | $ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
201 K | $ 12.11 | 0.08 % | $ 498 M | USA |